Analyst Ratings for [MYGN] Myriad Genetics, Inc.

3/12/25	Upgrades	Neutral Overweight	X
MYGN Myriad Genetics Piper Sandler
$11.50 $12.50
2/12/25	Initiated	Buy	X
MYGN Myriad Genetics Craig Hallum
$29
12/10/24	Initiated	Neutral	X
MYGN Myriad Genetics UBS
$18
12/9/24	Downgrades	Outperform Mkt Perform	X
MYGN Myriad Genetics Leerink Partners
$30 $21
9/19/24	Initiated	Equal-Weight	X
MYGN Myriad Genetics Morgan Stanley
$32
8/28/24	Initiated	Overweight	X
MYGN Myriad Genetics Wells Fargo
$35
6/27/24	Initiated	Sector Outperform	X
MYGN Myriad Genetics Scotiabank
$29
6/3/24	Resumed	Underperform	X
MYGN Myriad Genetics Jefferies
$20
5/8/24	Upgrades	Mkt Perform Outperform	X
MYGN Myriad Genetics Leerink Partners
$25 $35
12/21/23	Resumed	Neutral	X
MYGN Myriad Genetics Piper Sandler
$23
12/19/23	Initiated	Equal Weight	X
MYGN Myriad Genetics Wells Fargo
$20
12/14/23	Initiated	Buy	X
MYGN Myriad Genetics Guggenheim
$23
12/13/23	Initiated	Outperform	X
MYGN Myriad Genetics Wolfe Research
$28
7/5/23	Resumed	Underweight	X
MYGN Myriad Genetics JP Morgan
$18
5/23/23	Upgrades	Sell Buy	X
MYGN Myriad Genetics Goldman
$18 $25
1/18/23	Upgrades	Mkt Perform Outperform	X
MYGN Myriad Genetics Raymond James
$25
10/6/22	Initiated	Equal-Weight	X
MYGN Myriad Genetics Stephens
$22
10/15/21	Resumed	Market Perform	X
MYGN Myriad Genetics Cowen
$33
6/15/21	Initiated	Mkt Perform	X
MYGN Myriad Genetics Raymond James
6/3/21	Initiated	Sell	X
MYGN Myriad Genetics Goldman
$25
8/14/19	Downgrades	Overweight Neutral	X
MYGN Myriad Genetics Piper Jaffray
$45 $40
8/2/19	Upgrades	Underperform Neutral	X
MYGN Myriad Genetics BofA/Merrill
8/1/19	Upgrades	Underweight Eq Weight	X
MYGN Myriad Genetics Barclays
$18 $40
7/29/19	Downgrades	Strong Buy Hold	X
MYGN Myriad Genetics Needham
7/9/19	Downgrades	Outperform Mkt Perform	X
MYGN Myriad Genetics Cowen
3/12/19	Reiterated	Strong Buy	X
MYGN Myriad Genetics Needham
$37 $41
1/3/19	Initiated	Strong Buy	X
MYGN Myriad Genetics Needham
$36
11/30/18	Upgrades	Sell Neutral	X
MYGN Myriad Genetics Goldman
10/10/18	Upgrades	Neutral Overweight	X
MYGN Myriad Genetics Piper Jaffray
7/11/18	Upgrades	Eq-Weight Overweight	X
MYGN Myriad Genetics Morgan Stanley
3/21/18	Upgrades	Underweight Eq-Weight	X
MYGN Myriad Genetics Morgan Stanley
1/29/18	Initiated	Sell	X
MYGN Myriad Genetics Goldman
$32

MYGN Myriad Genetics, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.